论文部分内容阅读
复方纤溶酶原激和剂(Anisoylated plas-minogen streptokinase activator Complex;APSAC)可促进链激酶-纤溶酶原的活性。显效快,作用持久.本文旨在急性心肌塞(AMI)患者中采用静脉内 APSAC 与冠脉内链激酶(SK)治疗对比研究,以评价静注 APSAC 的再灌注疗效、安全性、耐受性、并比较两种溶栓治疗操作方法.方法:经血管造影证实冠脉闭塞的 AMI 患者,选75岁以下,具有急性缺血症状(胸痛)≥30分钟,ECG 示一个或多个肢导联 ST 段上抬≥0.1mV或胸导联≥0.2mV,且症状和体征不因含化硝酸甘油而减轻者为研究对象.伴为心源性休克,脑血管
Anisoylated plasminogen activator complex (APSAC) can promote streptokinase-plasminogen activity. Fast onset and long lasting effect.This paper aims to compare the efficacy of intravenous APSAC with coronary streptokinase (SK) in patients with acute myocardial infarction (AMI) to evaluate the efficacy, safety and tolerability of reperfusion after intravenous APSAC , And to compare two methods of thrombolytic therapy.Methods: AMI patients with coronary artery occlusion confirmed by angiography were selected under 75 years of age with acute ischemic symptoms (chest pain) ≥30 minutes, ECG showed one or more limb leads ST segment elevation ≥0.1mV or chest lead ≥0.2mV, and symptoms and signs not due to nitroglycerin and reduce those who study.Accompanied by cardiogenic shock, cerebrovascular